» Articles » PMID: 22369946

Identification of MiR-508-3p and MiR-509-3p That Are Associated with Cell Invasion and Migration and Involved in the Apoptosis of Renal Cell Carcinoma

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2012 Feb 29
PMID 22369946
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) have emerged as powerful regulators of multiple processes linked to human cancer, including cell apoptosis, proliferation and migration, suggesting that the regulation of miRNA function could play a critical role in cancer progression. Recent studies have found that human serum/plasma contains stably expressed miRNAs. If they prove indicative of disease states, miRNAs measured from peripheral blood samples may be a source for routine clinical detection of cancer. Our studies showed that both miR-508-3p and miR-509-3p were down-regulated in renal cancer tissues. The level of miR-508-3p but not miR-509-3p in renal cell carcinoma (RCC) patient plasma demonstrated significant differences from that in control plasma. In addition, the overexpression of miR-508-3p and miR-509-3p suppressed the proliferation of RCC cells (786-0), induced cell apoptosis and inhibited cell migration in vitro. Our data demonstrated that miR-508-3p and miR-509-3p played an important role as tumor suppressor genes during tumor formation and that they may serve as novel diagnostic markers for RCC.

Citing Articles

MiR-509-3p promotes gastric cancer development by activating FOXM1-mediated p38/MK2 pathway.

Jiang N, Kang J, Ding Y, Shataer M, Ma L, Tuersong T Biomol Biomed. 2024; 25(1):177-188.

PMID: 39319839 PMC: 11647255. DOI: 10.17305/bb.2024.11104.


Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis.

Razavinia A, Razavinia A, Jamshidi Khalife Lou R, Ghavami M, Shahri F, Tafazoli A Heliyon. 2024; 10(12):e32875.

PMID: 38948044 PMC: 11211897. DOI: 10.1016/j.heliyon.2024.e32875.


Use of Droplet Digital Polymerase Chain Reaction to Identify Biomarkers for Differentiation of Benign and Malignant Renal Masses.

Hayden J, Wiggins A, Sullivan T, Kalantzakos T, Hooper K, Moinzadeh A Cancers (Basel). 2024; 16(4).

PMID: 38398177 PMC: 10886675. DOI: 10.3390/cancers16040787.


Integrated analysis identifies microRNA-188-5p as a suppressor of AKT/mTOR pathway in renal cancer.

Shen H, Jin J, Wang H, Yu N, Liu T, Sheng H Cancer Sci. 2023; 114(8):3128-3143.

PMID: 37199297 PMC: 10394144. DOI: 10.1111/cas.15832.


Epigenetic reprogramming in cancer: From diagnosis to treatment.

Costa P, Sales S, Pinheiro D, Pontes L, Maranhao S, Pessoa C Front Cell Dev Biol. 2023; 11:1116805.

PMID: 36866275 PMC: 9974167. DOI: 10.3389/fcell.2023.1116805.